Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy
Metrics: PDF 1479 views | HTML 1373 views | ?
Sanchaika Gaur1,2,9, Yunfei Wen3, Jian H. Song1, Nila U. Parikh1, Lingegowda S. Mangala3,4, Alicia M. Blessing5, Cristina Ivan3,4, Sherry Y. Wu3, Andreas Varkaris1, Yan Shi5, Gabriel Lopez-Berestein4,6, Daniel E. Frigo5,7, Anil K. Sood2,3,4,8 and Gary E. Gallick1,2
1 Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
2 Program in Cancer Biology and Cancer Metastasis, The University of Texas Graduate School of Biomedical Sciences at Houston, TX, USA
3 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4 Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
5 Center for Nuclear Receptors and Cell Signaling, Departments of Biology and Biochemistry, University of Houston, TX, USA
6 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
7 Genomic Medicine Program, The Houston Methodist Research Institute, Houston, TX, USA
8 Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
9 Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, CA, USA
Gary E. Gallick, email:
Keywords: prostate cancer, miR-34a, bone metastasis, apoptosis, autophagy
Received: April 07, 2015 Accepted: July 11, 2015 Published: July 22, 2015
While several new therapies are FDA-approved for bone-metastatic prostate cancer (PCa), patient survival has only improved marginally. Here, we report that chitosan nanoparticle-mediated delivery of miR-34a, a tumor suppressive microRNA that downregulates multiple gene products involved in PCa progression and metastasis, inhibited prostate tumor growth and preserved bone integrity in a xenograft model representative of established PCa bone metastasis. Expression of miR-34a induced apoptosis in PCa cells, and, in accord with downregulation of targets associated with PCa growth, including MET and Axl and c-Myc, also induced a form of non-canonical autophagy that is independent of Beclin-1, ATG4, ATG5 and ATG7. MiR-34a-induced autophagy is anti-proliferative in prostate cancer cells, as blocking apoptosis still resulted in growth inhibition of tumor cells. Thus, combined effects of autophagy and apoptosis are responsible for miR-34a-mediated prostate tumor growth inhibition, and have translational impact, as this non-canonical form of autophagy is tumor inhibitory. Together, these results provide a new understanding of the biological effects of miR-34a and highlight the clinical potential for miR-34a delivery as a treatment for bone metastatic prostate cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.